NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Dr. Wendel Naumann of The Levine Cancer Institute, Virtual Presentation of STRO-002 Antibody-Drug Conjugate (ADC) at the American Association for Cancer Research (AACR) Virtual Annual Meeting 2020
Dr. Wendel Naumann of The Levine Cancer Institute, Non-Audio Presentation of STRO-002 Antibody-Drug Conjugate (ADC) at the American Association for Cancer Research (AACR) Virtual Annual Meeting 2020 Download Non-Audio Presentation CLICK HERE
Sutro Biopharma to Host Analyst and Investor Conference Call April 27, 2020 – PowerPoint Presentation
Download Presentation CLICK HERE
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
Summary of data for patients dosed at 2.9 mpk or higher in patients with heavily pre-treated ovarian cancer - 62% of patients saw a reduction in CA-125 levels of 50% or more or a normalization of CA-125 levels - 35% of patients who were evaluable for progression have...
American Association for Cancer Research (AACR) Virtual Annual Meeting 2020 – STRO-002 Abstract
STRO-002-GM1, a first in human, phase 1 Study of STRO-002, an anti-Folate Receptor alpha (FRα) Antibody Drug Conjugate (ADC), in Patients with Advanced Platinum-Resistant/Refractory Epithelial Ovarian Cancer (OC), including Fallopian Tube or Primary Peritoneal...
Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug Conjugate
-Company to present updated STRO-002 data at AACR Virtual Annual Meeting - SOUTH SAN FRANCISCO, Calif., April 20, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise...
Sutro Biopharma to Present Updated Clinical Data for its STRO-002 Antibody-Drug Conjugate at the AACR Virtual Annual Meeting on April 27, 2020
- Company to host a conference call following the presentation - SOUTH SAN FRANCISCO, Calif., April. 13, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), today announced that the company has been invited to present updated clinical data from its STRO-002 antibody-drug...
SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia
Foster City, CA, March 26, 2020 – SutroVax, a biopharmaceutical company dedicated to the delivery of superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the closing of a $110...
Sutro Biopharma Reports Full Year 2019 Financial Results and Recent Business Highlights and Developments
STRO-002 Data from an Ongoing Phase 1 Clinical Trial in Ovarian and Endometrial Cancers Late-Breaking Abstract was accepted by AACR; Sutro plans to announce updated data in second quarter 2020 STRO-001 Phase 1 Clinical Trial and Dose Escalation Ongoing in Multiple...
Sutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck
SOUTH SAN FRANCISCO, Calif., March. 12, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
10th Annual World ADC London 2020 – PowerPoint Presentation
To download the presentation, CLICK HERE